The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...
Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Welcome to today’s Biotech Spotlight, a series featuring companies that are creating breakthrough technologies and products. Today, we’re looking at Anokion, a Swiss biotech pioneering a vaccine to ...
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer ...
When Wall Street analyst Ronny Gal joined Swiss pharma giant Novartis in the newly created role of chief strategy and growth officer, he came to the table with industry know-how and an outsider’s ...
The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results